Among the patients with locoregional recurrence, those who received durvalumab after CRT showed a trend toward longer PFS compared with those who were not treated with durvalumab, although the difference was not statistically significant.
← all excerpts
Durvalumab consolidation after chemoradiotherapy for locoregional recurrent non-small cell lung cancer.
1
—
—